Drugs that contain Osimertinib Mesylate
1. Drug name - TAGRISSO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(9 years from now) | |
| US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(9 years from now) | |
| CN105254616A | ASTRAZENECA | Substituted N-(2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof |
Jul, 2032
(9 years from now) | |
| CN104109161B | ASTRAZENECA | 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer |
Jul, 2032
(9 years from now) | |
| CN104109151B | ASTRAZENECA | N - (2 - (2-Methylamino)--4 - Methoxy - -5-[4 - (1-Methyl-Indole - -3 - Yl) Pyrimidine - -2 - Yl] Amino} Phenyl) -2 - Acrylamide Mesylate Polymorph |
Jul, 2032
(9 years from now) | |
| CN103702990B | ASTRAZENECA | 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer |
Jul, 2032
(9 years from now) | |
| CN104109161A | ASTRAZENECA | 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer |
Jul, 2032
(9 years from now) | |
| CN105348266B | ASTRAZENECA | Substituted 3-Chloro-N - (3 - (Pyrimidin - -2 - Ylamino) Phenyl] Propanamide Or A Salt Thereof |
Jul, 2032
(9 years from now) | |
| CN105254616B | ASTRAZENECA | Substituted N - (2-Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof |
Jul, 2032
(9 years from now) | |
| CN105175396B | ASTRAZENECA | Substituted 4-Methoxy -N3-(Pyrimidin - -2 - Yl) Phenyl]--1, 3-Diamine Compound And Salt Thereof |
Jul, 2032
(9 years from now) | |
| CN105198862B | ASTRAZENECA | Substituted N - (4-Fluoro - -2 - Methoxy - -5 - Nitrophenyl) Pyrimidine - -2 - Amine Compound And Salt Thereof |
Jul, 2032
(9 years from now) | |
| CN104109151A | ASTRAZENECA | 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer |
Jul, 2032
(9 years from now) | |
| CN105175396A | ASTRAZENECA | A Substituted 4-Methoxy-N3-(Pyridine--2-Yl) Benzene-1, 3-Diamine Compound And Salt Thereof |
Jul, 2032
(9 years from now) | |
| CN105198862A | ASTRAZENECA | Substituted N-(4-Fluorin--2-Methoxy-5-Nitrophenyl) Pyrimidine-2-Ammine Compound And Salt Thereof |
Jul, 2032
(9 years from now) | |
| CN103702990A | ASTRAZENECA | 2 - (2, 4, 5-Substituted Aniline) Pyrimidine Derivatives As Egfr Tuning Sub-Used For Treating Cancer |
Jul, 2032
(9 years from now) | |
| CN105348266A | ASTRAZENECA | Substituted 3-Chlorine-N-[3-(Pyridine--2-Ylamino) Phenyl] Propanamide Or Salt |
Jul, 2032
(9 years from now) | |
| IN297581B | ASTRAZENECA | 2 - (2, 4, 5 - Substituted -Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer |
Jul, 2032
(9 years from now) | |
| EP3686194A1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds |
Jul, 2032
(9 years from now) | |
| EP3686194B1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds |
Jul, 2032
(9 years from now) | |
| EP3686193B1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds |
Jul, 2032
(9 years from now) | |
| EP3686193A1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Compounds |
Jul, 2032
(9 years from now) | |
| EP2736895A1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer |
Jul, 2032
(9 years from now) | |
| EP3009431A1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer |
Jul, 2032
(9 years from now) | |
| EP3333161A1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer |
Jul, 2032
(9 years from now) | |
| EP3333161B1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer |
Jul, 2032
(9 years from now) | |
| EP3009431B1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino)Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer |
Jul, 2032
(9 years from now) | |
| EP2736895B1 | ASTRAZENECA | 2-(2,4,5-Substituted-Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer |
Jul, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(12 years from now) | |
Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | TABLET;ORAL | Prescription |
| EQ 80MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.